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I. INTRODUCTION, LITERATURE BACKGROUND 
 
Epidemiology of head injury  
 Traumatic brain injury (TBI) is the leading cause of mortality in the active/working 
population and a major cause of disability in people under the age of 35. While the mortality 
rate of head injuries is 20-25% in western societies, this figure in Hungary is 45%. In Europe 
1.600.000 head injured patients receive hospital care, producing a brain injury rate of 
235/100.000/year. The leading causes of TBI are traffic accidents, falls, violence and sport 
related injuries. The most imperiled demographic groups are males and individuals living in 
regions characterized by socioeconomic deprivation.  
 The average cost per inpatient with severe traumatic injury is around 6,000 Euro in the 
most developed European countries. The costs due to initial hospitalization are only a small 
part of total costs. A total lifetime costs per TBI case in the US is around $200.000. 
According to some estimates TBI will become the third most common cause of death globally 
by the year 2020. 
 
Classification of head injuries  
The most commonly used method of determininge injury severity is the Glasgow 
Coma Scale (GCS) developed by Teasdale et al., which distinguishes mild (GCS=13-15), 
moderate (GCS=9-12), and severe (GCS=3-8) injuries. According to the traditional 
classification of head injuries we can discern open and closed injuries. Patomechanisms of 
injury are differentiated as primary or secondary changes. Primary injuries are the result of 
mechanical forces that producetissue damage at the moment of injury. The damage may affect 
blood vessels, axons, neurons, and glia in a focal or diffuse pattern.  
 
Diffuse axonal injury 
 Diffuse axonal injury (DAI) is the sum of all axonal changes caused by traumatic 
brain injury, which are scattered throughout the brain in the midst of normal axons in a widely 
distributed in mostly normal parenchyma.  
 DAI has two distinct morphological appearances: axonal swelling/axonal bulb 
formation (AS/B) and ultrastructural (neurofilament) compaction (NFC). There are many 
different animal models for DAI, however, none of these are able to represent 100% of the 
overall dimension and time course of human DAI. Therefore in animal models axonal injuries 
are called traumatic axonal injury (TAI), while DAI is used for human cases. 
 
Axonal swelling/axonal bulb formation (AS/B) 
The phenomenon of diffuse axonal injury was first described by Strich et al. After post 
mortem examination of the white matter of severely head injured patients, balloon-like axonal 
dilations were observed in a scattered pattern along intact axons, while wallerian and myelin 
degratation was observed on the distal segment. The currently used name for DAI comes from 
Adams. Since Strich, Adams and his colleagues emphasized the first time, that axonal injury 
is a primary consequence of head injury, and it does not develop as a consequence of 
secondary injury. According to Povlishock et al., these axonal damages are induced by 
shearing forces caused by moderate or severe traumatic brain injury. They found that DAI 
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process that is gradually ongoing in time in the majority of the damaged axons. During this 
process, focal axolemmal permeability disruption occurs almost immediately (<5 minutes) 
post-injury along in the injured axonal segments.  
Focal damage of the axolemma is accompanied by morphological characteristics, such 
as the swelling of mitochondria, disappearance of neurotubules, neurofilament modifications 
and impaired anterograde axonal transport. This results in the accumulation of carried cell 
components and other substances, that manifest in axonal swelling. Over time, the axonal 
swelling increases, resulting in the detachment of the affected axonal segment in a ballon 
form, creating proximal axonal bulbs. The distal axonal segment undergoes wallerian 
degeneration.  
The time lapsed from the beginning of axonal alterations until the formation of 
axonbulbs and axonal disconnection depends on the severity and type of trauma, and on the 
species. In humans, this time is measured in hours and days, thus the available therapeutic 
time frameis much longer than in experimental animals. 
 
Ultrastructural (neurofilament) compaction (NFC) 
 Ultrastructural compaction was discovered by Povlishock et al. with 
electronmicroscopic analysis of the brainstem in immediate (5 minutes) post injury perfused 
animals. They observed that the distance between neurofilament sidearms was almost halved, 
and the number of microtubules and neurofilament was greatly reduced. Based on their 
theory, the mechanism of NFC is the following: as a consequence of head injury, small sized 
pores are opening on a short section of the affected axon (mechanoporation), the regulatory 
role of axolemma is terminated and calcium ions enter into the axon. The greatly increased 
concentration of calcium results in calpain activation, which cleaves non-erythroid alpha-II 
spectrin to 145 and 150 kD sized subunits (calpain-mediated spectrin proteolysis, CMSP). 
Spectrin is a constituent of the subaxolemmal cytosceletal network, and it can also be found 
around the mitochondria as well. In the early phase (15-30 minutes) the cleavage of spectrin is 
localized to the subaxolemmal and perimitochondrial area, then it shifts to the cytosceletal 
network of the affected axon, and its degradation causes further permeability disturbance, and 
the activation of intra-axonal proteolytic cascades, which in turn leads to irreversible axonal 
damage.  
 For the histological detection of NFC, RMO-14 antibody is used against of the 
medium-sized neurofilament subunit (NF-M). After the dephosphorilation of the 
neurofilament’s sidearm, RMO-14 antibody is able to bind to the “rod domain” of NF-M. 
Earlier observations assumed that NFC and AS/B occur in the same damaged axons. Today, 
however, it has become clear that in most cases, these two morphological changes occur in 
different axon populations and rarely within the same axon. 
 
Experimental therapeutic influence of diffuse brain injury  
Pituitary adenylate-cyclase activating polypeptide (PACAP)  
 Both necrotic and apoptotic enzyme cascades play a role in DAI, therefore processes 
that are likely to inhibit both, deserve special consideration. This dual targeting is especially 
important, since according to some researchers, the inhibition of apoptotic processes cannot 
save neurons after mitochondrial damage, such as the dissociation of electron-transport chain, 
and cytochrome c release. Instead of apoptotic cell death, it causes only the activation of 
necrotic cascade, therefore, and evokes a shift between the two enzymatic processes. 
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 PACAP is a member of the vasoactive intestinal peptide (VIP)/secretin/glucagon 
family and was first isolated from the pituitary gland.  
 In vitro studies demonstrated PACAP’s anti-apoptotic and anti-inflammatory effects. 
In vivo studies indicated that PACAP crosses the blood-brain barrier (BBB) and is equally 
effective before and after administration in rats’ experimentally induced global and focal 
cerebral ischemia, as well as in retinal degeneration.  
 In the last few years, our research group examined the neuroprotective effect of 
PACAP in a model of diffuse experimental TBI. The effective dose in earlier studies with 
cerebral ischemia (125 µg administered intravenously (i.v.) prior to injury), did not exert a 
beneficial effect in TAI, however, intracerebroventricular (i.c.v.) injection proved to be 
effective. The treatment dose in our experiment was based on the results of the above 
mentioned research group, that treatment with an i.c.v. injection of 100 µg PACAP was able 
to significantly reduce the density of impaired axons in the corticospinal tract (CSpT). 
 
Poly(ADP-ribose)polymerase (PARP)-inhibition  
PARP was known as a DNA repair enzyme. It is activated by DNA breakage caused 
by oxidative stress, resulting in the transfer of ADP-ribose units from NAD
+
 to nuclear 
proteins. The overactivation of this highly energy demanding process, induced by cumulative 
stress, results in the depletion of NAD
+
, loss of ATP, and through the collapse of the energy 
homeostasis of the cell, it may result in cell death.  
While long-term inhibition of PARP may induce carcinogenesis and mutagenesis, it 
may contribute to the normalization and maintenance of the energy homeostasis in the acute 
stage.  
Komjáti et al. have recently (2005) found, that PARP inhibition not only inhibits free 
radical-induced necrosis, it plays a direct a role in initiating apoptotic processes via apoptosis-
inducing factor (AIF). Furthermore PARP modulates the release of inflammatory mediators 
and cytokines via NF-kappaB pathway.  
In recent years, several PARP inhibitors have been tested in various models of TAI, 
including 3-aminobenzamide, which significantly reduced the extension of lesion size in cold-
induced brain injury-model. Interestingly, similarly to the neuroprotective effect of calpain 
inhibition, the pathobiological of the effect of PARP-inhibition has not been revealed yet.  
 In our experiments, we examined the effect of the newly developed PARP-inhibitor, 
L-2286 (2-[(2-piperidin-1-yletil)thio]quinazolin-4(3H)-one) in Marmarou’s impact 
acceleration head injury model.  
 
Diffuse neuronal injury (formation of “dark” neurons) 
 More than a century ago it was discovered that the brains of those patients who died of 
various neurological diseases, contained neurons whose nucleus, cytoplasm and main 
dendrites were dramatically shrunken. These neurons had increased affinity to bind basic 
neurohistological dyes. Traditionally these cells were called “dark” neurons. Since the early 
80’s the presence of “dark” neurons was described in a numerous animal models of different 
neurological diseases (hypoglycemia, hyperglycemia, status epilepticus, focal ischemia and 
four-vessel ischemia). 
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 In the early 90’s, Gallyas et al. observed that “dark” neurons and axons can be 
produced by both in vivo, and post mortem mechanical injury. According to 
electronmicroscopic observations, the ultrastructural elements are intact, but were dramatically 
compacted (ultrastructural compaction) in all freshly produced “dark” neurons. Those cells had 
an increased electrondensity, their endoplasmic reticulum (ER) cisternae were contracted, and 
Golgi cisternae were dilated, while the mitochondria and tother multivesicular bodies remained 
unchanged in volume. A characteristic of “dark” neurons is, that if the soma of a neuron is 
affected, its dendritic tree is also effected, and vice versa. 
This phenomenon can be explained the compaction starts at one single point on each 
soma-dendrite domain, and then it spreads to the whole soma-dendrite domain. Gallyas et al. 
(1992) explained the mechanism of this progression by the cytoplasm of neurons (and other 
cells) containing a microtrabecular gel-structure, which is anchored to ultrastructural 
elements, that stores free energy in non-covalent bindings. After the initialization of this gel-
structure at a single point, it is capable of propagating a phase transition (gel-to-gel phase 
transition) through the impact of stored energy. Those gels have two or more metastabile 
stages. Each metastable stage with different energy levels belongs to a different polymer-
molecule conformation, different water content and different volume. After transmission of 
sufficient activation energy to the higher energy level stage, its one single point switches over 
to a stage of lower energy value, but energetically more stable level. This released energy 
serves as activation energy, and initiates chain-reaction on the neighboring points (domino-
principle). In the case of “dark” neurons, the phase transition can be initialized by 
pathometabolic processes (ischemia, hypoglycemia, status epilepticus or mechanic impact). 
Contraction of gel-structure pulls to itself other anchored ultrastructural elements and 
squeezes out fluid from the soma-dendrite domain along with the affected axon-sections. 
 
 
II. AIMS 
 I intended to investigate new experimental therapy opportunities that influence 
diffuse axonal injury, and aimed to explore the further details of the formation of 
ultrastructural compaction. During my work the following questions were examined: 
 
1., Does the PACAP have a neuroprotective effect in the rat head injury model of 
central fluid percussion (CFP)?  
2., Does the newly developed L-2286 PARP inhibitor have a neuroprotective effect in 
the rat head injury model of Marmarou’s impact acceleration?  
3., What is the fate of (ultrastructural compacted) “dark” neurons produced by 
transient focal cerebral ischemia in a non-necrotic and non-excitotoxic environment?  
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1. THE EFFECT OF PACAP TREATMENT IN THE CENTRAL FLUID 
PERCUSSION HEAD INJURY MODEL  
 
1.1. MATERIALS AND METHODS  
Animals 
Male Wistar rats weighing 350-380 g were housed in cages with free access to food 
and water in the animal facility of the Department of Neurosurgery in Pécs.  
 
Rat central fluid percussion injury model 
 Animals were pre-anesthetized in a bell jar for 5-minutes with a mixture of 4% 
isoflurane, 70% N2O and 30% O2. After endotracheally intubating the animals, anesthesia was 
maintained with a mixture of 1-2% isoflurane in 70% N2O and 30% O2. Thereafter animals 
were placed in a stereotactic device and a midline incision was made to expose the skull from 
the bregma to the lambda. Two 1-mm holes were drilled in the dried right frontal and occipital 
bones 1 mm from the bregma and the lambda, for the insertion of fixation screws to secure the 
“crown”. A 4.8 mm-diameter craniotomy was then made, centered in the midline between the 
bregma and the lambda above the intact dura. A plastic injury cap was then affixed over the 
craniotomy using silicone adhesive and cyanoacrylate. As a main part of the “crown” a plastic 
injury cap was affixed over the craniotomy. Dental acrylate was applied around the cap and 
the two earlier fixated screws, to make the "crown" at same height level as the cap. When the 
dental cement was completely hardened, the injury cap was filled with 0.9% saline. 
Anesthesia was then discontinued and animals were attached to the fluid percussion device 
and were subjected to an injury at a magnitude of 2 atm, which is considered to be of 
moderate severity. Sham-injured controls were prepared for injury in the same manner but 
were not injured. After the injury, rats were monitored for the recovery of spontaneous 
respiration, if spontaneous respiration was not evident after 20 seconds, animals were rapidly 
reintubated and ventilated with 100% O2 until spontaneous respiration was regained.  
 
I.c.v. PACAP treatment 
 A single bolus of 100 µg PACAP was dissolved in 5 µl physiological saline and 
administered i.c.v. 30 min after injury in to the right ventricle (AP:-1.0; L: 1.5; V:-3.5 from 
the bregma). The vehicle-treated group received the same volume of physiological saline in 
the same way.  
 
Immunohistochemistry 
 Two hours after injury rats were sacrificed with an intraperitoneal (i.p.) injection of 
sodium pentobarbital, and were transcardially perfused with 4% paraformaldehyde. Brains 
along with the brainstem were removed and immersed in 4% paraformaldehyde overnight. A 
medial, 5-mm-wide block of the brain was excised using a sagittal brain blocking device, and 
30 µm vibratome sections were made. Until the start of the immunohistochemical procedure, 
slides were stored in 0.1 M phosphate buffered saline.  
 Two immunohistochemical protocols were used. For the detection of impaired 
axoplasmic transport we used a polyclonal antiserum targeting the C-terminus of betha-
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amyloid precursor protein (β-APP). For the detection of NFC, an RMO-14 antibody was used, 
which is able to bind to the rod domains of altered neurofilament NF-M subunits.  
 
Histological analysis with Image-Pro Plus v5.0.1 
 APP or RMO-14 immunopositive (IP) axonal profiles were examined using a light 
microscope interfaced with a digital camera and a computer-assisted image analysis system 
(Image Pro Plus v5.0.1). According to previous descriptions of the main foci affected by DAI 
the area of the CSpT and the medial longitudinal fascicle (MLF) of the brainstem were 
analyzed. 
 
Statistical analysis 
 Differences between the densities of IP axonal profiles (expressed as mean 
number/mm
2
) in PACAP and vehicle-treated rats ware compared with Student t-test. A 
difference was considered significant when p value was less than 0.05. 
1.2. RESULTS 
 After light microscopy and statistical analysis we concluded that treatment with 100 
µg PACAP 30 min after the induction of moderate CFP injury resulted in a significant 
reduction in the density of APP- and RMO-14 IP axonal profiles in the CSpT, compared to 
vehicle-treated animals. In the MLF, no significant difference was observed between the 
densities of APP- or RMO-14 IP axons in PACAP versus vehicle-treated animals (Table 1.). 
 
APP IP 
axons 
Vehicle PACAP 
RMO-14 
IP axons 
Vehicle PACAP 
CSpT 560.96±64.36 
290.04±36.93 
(p<0.05) 
CSpT 283.31±29.91 
155.71±31.52 
(p<0.05) 
MLF 307±24.17 265.57±10.81 MLF 272.31±20.1 265.7±33.46 
 
Table 1. Mean density of APP and RMO-14 IP axons in the CSpT and in MLF in PACAP 
versus vehicle-treated animals. Data expressed as mean number/mm
2
 ± SEM. p <0.05 versus 
vehicle-treated rats 
 
1.3. DISCUSSION AND CONCLUSION 
Our work is the first study which demonstrated in the CFP model the neuroprotective 
effect of PACAP in TAI. Our results confirmed previous findings from the impact 
acceleration model of diffuse TAI, indicating that PACAP is an efficient inhibitor of impaired 
axoplasmic transport and NFC associated with axonal injury. Furthermore, the results were 
consistent with previous investigations demonstrating the neuroprotective effects of PACAP 
in vitro conditions and in vivo observations. In vitro, PACAP effectively inhibited apoptosis 
in various cell lines. In vivo, PACAP reduced the infarct size in models of both transient and 
permanent focal cerebral ischemia. In global cerebral ischemia i.c.v. or i.v. PACAP treatment 
prevented ischemic neuronal death in the CA1 region of the hippocampus. In models of 
Parkinson's disease it protects the dopaminergic nigrostriatal neurons from apoptotic cell 
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death. PACAP significantly inhibited the activation of caspases and other key molecules in 
the apoptotic cascade, playing important roles in the pathogenesis of TBI. A change in 
intraaxonal mitochondrial integrity plays an important role in the outcome of TBI. A 
pathological accumulation of calcium in the mitochondria inactivates the function of aconitase 
enzyme, a key mitochondrial enzyme that influences the viability of neurons. PACAP is 
capable of influencing this altered mitochondrial integrity through the inhibition of aconitase 
inactivation.  
The key finding of this study is that i.c.v. administration of 100 µg PACAP 30 min 
after moderate CFP injury significantly reduced the density of both APP and RMO-14 IP 
axons. Eventhough impaired axoplasmic transport is not the only process that leads to axonal 
death, the prevention of such impairment and the discontinuity of anterograde transport 
should be considered one of the cornerstones in the therapy of diffuse TBI. It is important to 
note that the neuroprotective effect of PACAP was only proven significant in the CSpT. In 
this tract the density of damaged axons as well as their diameter and course are different from 
those analyzed in the MLF, this may partly account for the differences in our results. In the 
last few decades, despite the extensive research and testing for potential novel candidates 
capable of inhibiting the pathobiological mechanisms associated with the formation of DAI, 
none of the substances tested in clinical trials were proven to be effective.  
In summary our experiments, we demonstrated that PACAP is capable of exerting its 
axono-protective effect not only in impact acceleration, but also in an animal model of CFP 
diffuse axonal injury. Based on previous and present findings, PACAP is considered a 
potential candidate for clinical trials in TBI.  
 
2. L-2286: THE EFFECTS OF A NEW PARP INHIBITOR IN A RAT IMPACT 
ACCELERATION HEAD INJURY MODEL  
 
2.1. MATERIALS AND METHODS 
Animals 
Male Wistar rats weighing 300-350 g were housed in cages with free access to food 
and water in the animal facility of the Department of Experimental Zoology and 
Neurobiology, University of Pécs.  
 
Marmarou’s rat impact-acceleration head injury model 
All rats were first anesthetized in a bell jar for 5 min with 4% isoflurane in 70% N2O 
and 30% O2. After endotracheal intubation, rats were ventilated with 1.5% isoflurane in 70% 
N2O and 30% O2. A midline incision was made to expose the skull from the bregma to the 
lambda sutures. A stainless steel disc (10 mm in diameter and 3 mm thickness) was fixed 
centrally between the lambda and the bregma sutures using cyanoacrylate. To create a severe 
head injury, a 450 g weight was dropped from 2 m onto the stainless disc fixed to the rat’s 
skull. After impact, the metal disc was removed and the animals were monitored during the 
recovery of spontaneous respiration. If spontaneous respiration it was not evident after 20 
seconds, animals were rapidly reintubated and ventilated with 100% O2 until spontaneous 
respiration was regained. Sham-injured animals were prepared for injury in the same way, but 
were not injured. 
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Establishment of dose-response curve for i.c.v. L-2286 
Thirty minutes after injury, a single bolus of 10, 50 or 100 µg/rat of L-2286 dissolved 
in 5 µl of physiological saline was administered in to the right ventricle through a craniotomy 
(AP:-1.0; L: 1.5; V:-3.5 to bregma). The vehicle-treated group received the same volume of 
physiological saline using the same method. Two hours post-injury, animals underwent the 
procedure that was described in earlier ”Immunohistochemistry”, with the only difference, 
that only the density of damaged APP IP axons in CSpT was determined.  
 
Experimental protocol to test the post-injury administration regime 
Half of the animals were treated immediately, and the another half 30 minutes post-
injury trough the above mentioned method with a single bolus of i.c.v. 100 µg/rat L-2286. 
According to the two treatment time-points, we treated the vehicle-treated group with 5µl/rat 
of physiological saline as the L-2286 treated rats were. Two hours post-injury, animals 
underwent the procedure that was described in ”Immunohistochemistry”. 
 
Histological analysis with Image-Pro Plus v5.0.1 
 APP IP axonal profiles were examined using a light microscope interfaced with a 
digital camera and a computer-assisted image analysis system (Image Pro Plus v5.0.1).  
 
Statistical analysis 
 Differences between densities of IP axonal profiles (mean number/mm
2
) in L-2286- 
and vehicle-treated groups were compared with Student’s T-test, results were considered 
statistically significant when p value was less than 0.05. 
 
Beam-balance test 
One day before the injury animals were repeatedly trained until they were capable of 
balancing on a 1.5-cm-wide square wooden bridge - suspended 60 cm above a foam pillow- 
for three consecutive trials of 60 sec each. All animal groups were tested 1 hour and 1-7 days 
after injury and scores from each group were analyzed. The scoring scale was the following: 
1: balances with steady posture; 2: grasps the side of the beam and/or has unsteady 
movements; 3: hugs the beam or slips without falling; 4: attempts to balance on the beam but 
falls off; 5: drops over the beam or hangs on the beam and falls off and 6: does not attempt to 
balance on the beam. 
Open-field test 
 The open-field test was used to measure spontaneous locomotor activity. The open-
field is a box with a 70 × 70 cm floor and a height of 50 cm. Eighth days post–injury, rats 
were brought into the experimental room where they remained in their transfer cages for 30 
min (acclimatization), after which each subject was placed for 5 minutes into the center of the 
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open-field box. Crossing, rearing and grooming were recorded with a video camera during the 
5-minute test.  
 
Elevated plus-maze test 
The elevated plus-maze was used to measure anxiogenic behavior. The maze consists 
of 4 intersecting arms: 2 arms are fully open (open arms), while the other 2 are surrounded 
with 3 walls (closed arms). All rats were placed in the center of the maze and the following 
parameters were recorded for 5 minutes: number of head dips into the open arms, entries with 
the first limbs into the open arms, and the time spent in closed or open arms. 
 
Statistical analysis 
Test-results of each rat in the different experimental groups were totaled. Results of 
the beam-balance test were analyzed by one-way ANOVA with non-parametric Dunn’s post 
hoc tests. Results of the open-field and the elevated plus-maze were analyzed by one-way 
ANOVA with Dunnett post hoc tests. In both tests the differences between groups were 
considered significant when p<0.05 and p<0.01.  
 
2.2. RESULTS  
Dose-response curve of i.c.v. L-2286 
Thirty minutes post-injury treatment with 10 µg/rat of L-2286 i.c.v. did not reduce the 
density of APP IP axons in the CSpT. Eventhough 50 µg/rat of L-2286 i.c.v. reduced the 
density of damaged profiles, but that difference compared to vehicle-treated rats was not 
statistically significant. Of the three examined doses, only the 100 µg/rat of L-2286 i.c.v. was 
able to reduce significantly the density of APP-IP axons in CSpT (Table 2.). 
 
 Vehicle 10 µg 50 µg 100 µg 
Density  345.61±41.56 348.09±13.08 255.58±10.72 
87.61±8.86 
(p<0.01) 
 
Table 2. The effect of i.c.v. L-2286 administered in different doses 30 min after severe impact 
acceleration head injury on the density of APP IP axons in the CSpT. Data expressed as mean 
number/mm
2
 ± SEM (p < 0.01 compared to vehicle-treated group). 
Therapeutic window 
In the case of both APP and RMO-14 IP axons, 100 µg/rat L-2286 administered i.c.v. 
immediately, or 30 min post-injury; both treatments have reduced the density of impaired 
axons in similar degrees both in CSpT and in MLF, compared to vehicle-treated animals. 
However, in the case of RMO-14 IP axons, immediate post-injury treatment seemed to be 
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more effective, since a significant difference was observed in the density of damaged axons in 
both CSpT and MLF compared to treatment 30 min post injury (Table 3.). 
 
APP IP 
axons 
Vehicle 
L-2286 
immediately 
post-injury 
L-2286 30min 
post-injury 
CSpT 345.61±41.56 
72.50±8.54 
(p<0.01) 
87.61±8.86 
(p<0.01) 
MLF 285.33±48.90 
45.59±4.09 
(p<0.01) 
71.17±7.23 
(p<0.01) 
RMO-14 
IP axons    
CSpT 88.29±6.55 
5.56±2.98 
(p<0.01) 
45.81±5.04 
(p<0.01) 
MLF 131.66±21.39 
16.01±3.04 
(p<0.01) 
42.92±2.3 
(p<0.01) 
 
Table 3. Densities of APP and RMO-14 IP axons in CSpT and MLF in animals treated 
with 5 µl/rat of i.c.v. vehicle and 100 µg/rat of L-2286 i.c.v. immediately, and 30 min post-
injury. Data expressed as mean number/mm
2
 ± SEM (p < 0.01 compared to vehicle-treated 
group) 
Effect of 100 µg/rat L-2286 i.c.v. in beam-balance test 
Vehicle-treated animals had the worst motor performance of the four assessed groups. 
Until the last test day, the animals in this group had not reached the performance level of 
sham-injured animals. Immediate post-injury treatment with 100 µg/rat L-2286 i.c.v. 
significantly improved motor performance at one hour post injury, compared to vehicle-
treated animals. The group treated 30 min post-injury reached the maximum possible score on 
the fourth day (score 1). The motor performance of this group was significantly improved 
from the second examined time-point (one day) to the last time-point (seventh day) compared 
to the vehicle-treated group. 
Comparison of two treatments shows that both treatments improved the impaired 
motor functions in the balance-beam test, but treatment with 100 µg/rat L-2286 i.c.v 30 
minutes post-injury was more effective than treatment immediately after trauma (Table 4.). 
 
Effect of 100 µg /rat L-2286 i.c.v. in open-field test  
 Immediate post-injury treatment with L-2286 did not significantly improve any of the 
three examined parameters compared to vehicle-treated animals. However, L-2286 treatment 
30 min post-injury significantly improved the number of grooming activities compared to the 
vehicle-treated group, without any effect on the another two parameters (crossing and rearing) 
(Table 4.). 
Effect of i.c.v. 100 µg /rat L-2286 in elevated plus-maze test 
 Results of the elevated plus-maze test showed, that the anxiety level was significantly 
lower in both L-2286-treated groups compared to the vehicle-treated animals, since rats spent 
significantly more time in the open arms than in the closed arms. Interestingly, the group 
treated immediately post-injury with L-2286, not only spent significantly more time in the 
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open arm than the vehicle-treated group, but also the sham-injured group. This finding was 
not observed in rats treated 30 min post-injury (Table 4.).  
 
Beam-balance 
Sham injured Vehicle L-2286 
immediately post-
injury 
L-2286 30 min post-
injury 
1h (score) 1 6 3.8±0.58 p<0.05 4.8±0.2 
1 day (score) 1 5.6±0.24 3.4±0.4 2.6±0.24 p<0.01 
2 day (score) 1 4.8±0.2 3±0.55 2.4±0.24 p<0.05 
3 day (score) 1 5.2±0.2 2.6±0.6 1.4±0.24 p<0.01 
4 day (score) 1 4 2±0.55 1 p<0.01 
5 day (score) 1 3.8±0.2 2.2±0.73 1 p<0.01 
6 day  (score) 1 3±0.32 2±0.55 1 p<0.01 
7 day (score) 1 2.2±0.22 1.6±0.67 1 p< 0.05 
Open-field   
Crossing (piece) 117.4±2.77 75.8±6.09 98.4±11.45 90±15.99 
Grooming (piece) 33±3.61 19.8±1.39 28.6±2.5 30.6±4.37 p< 0.05 
Rearing (piece) 1.4±0.93 1.2±0.97 0.6±0.24 1.2±0.73 
Elevated plus-maze   
Head dips in to open arm (piece) 6±1.58 10.4±0.51 7±1.13 p<0.05 6.6±1.21 p< 0.05 
Enter in to open arm piece) 4.4±1.21 2.6±0.87 3.6±0.26 3.2±0.66 
Time in open arm (sec) 46.8±10.17 1.6±0.98 78.8±2.11 p<0.01 68±13.67 p<0.01 
Time in closed arm (sec) 253.2±10.17 298.4±0.98 221±2.11 p<0.01 232.2±13.67 p<0.01 
Grooming in closed arm 17.6±0.98 12.6±0.51 12.2±1.18 15.4±2.16 
 
Table 4. Effect of 100 µg/rat L-2286 i.c.v. immediately and 30 min post-injury in 
beam-balance, open-field and elevated plus-maze tests. Data expressed as mean number ± 
SEM (p < 0.05 and p < 0.01 compared to vehicle-treated group) 
 
2.3. DISCUSSION AND CONCLUSION 
Based on former observations with Marmarou’s impact acceleration head injury 
model, this model results in the impairment of both motor and cognitive functions. In our 
experiments, to reveal the effectivness of L-2286, we used special immunohistochemical 
markers of DAI, which reflect NFC and impaired axoplasmatic transport. Based on the results 
of the two markers, our results indicated that the extent of axonal damage was significantly 
reduced both in CSpT, which represents the tract of motor functions, and in MLF, which 
carries sensoric information. The differences in APP and RMO-14 IP axon density reduction 
confirms the observation, that axonal damage is a heterogenous phenomena, it does not means 
that the same pathological procedures will be activated in each neuronal fiber.  
Based on the experiments apraising of functional outcome, we established, that in this 
animal model of DAI, -which primarily affects the motor system -, post-treatment with PARP 
inhibitor was able of improving impaired motor performance, and of reducing the level of 
anxiety caused by traumatic brain injury. Namely, it improved the functional outcome. 
Although the present experiments not provide an answer, whether the positive effect of 
PARP-inhibition is caused by only of the inhibition of DAI, or in Marmarou’s head injury 
model it may have played a role in deflecting diffuse neuronal damage. 
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3. THE FATE OF “DARK” NEURONS PRODUCED BY TRANSIENT FOCAL 
CEREBRAL ISCHEMIA IN A NON-NECROTIC AND NON-EXCITOTOXIC 
ENVIRONMENT: NEUROBIOLOGICAL ASPECTS 
   
Four morphological subtypes of “dark” neurons are currently known: the Huntington 
type (observed in a mouse model of experimental Huntington disease), the artefactual type 
(produced by unintentional post mortem mechanical injuries of various kinds), the reversible 
type (early stages of hypoglycemic, epileptic or ischemic injury) and the irreversible type (late 
stages of hypoglycemic, epileptic or ischemic injury). During the past few years, some 
researchers have published novel ideas of general neurobiological characters of common 
nature, common mechanism of formation and common mode of death of the “dark” neurons 
produced in a visibly normal environment by a head injury, an electric shock or mild 
hypoglycemia. We can conclude that “dark” neurons have a cellbiological type; the above 
mentioned four morphological types are the “forced consequences” of their pathological 
environment. 
 In this experiment we followed up in time the morphological changes of “dark” 
neurons -produced by a one-hour intraluminal filament occlusion technique of arteria cerebri 
media.  
3.1. MATERIALS AND METHODS 
 
Animals 
Male Wistar rats weighing 200-220g were housed in cages with free access to food 
and water in the animal facility of the Department of Neurosurgery in Pécs. 
 
Rat transient focal cerebral ischemic model  
 Animals were anesthetized with a mixture of 2.5% isoflurane, 30% oxygen and 67.5% 
nitrous oxide during the experiments. The right arteria cerebri media was occluded for one 
hour by the injury technique of Koizumi et al. The region of the right carotid arteries was 
exposed, and the external carotid artery, the common carotid artery and its pterygopalatine 
branch were ligated during the surgery. A 4-0 nylon surgical thread with a flame-rounded tip 
was inserted into the origin of the middle cerebral artery through an incision in the external 
carotid artery and kept there for 1 h. Finally, the filament was pulled out and the circulation 
was re-established. Immediately thereafter, a few rats were perfused transcardially with 500 
ml of a glutaraldehyde fixative. The other animals were assigned different survival times. At 
these time-points, rats were i.p. administered with a 1:1 mixture of 25 mg/ml thiopental and 5 
mg/ml diazepam in 2ml/bodyweight before perfusion fixation. In the case of glutaraldehyde 
fixation, the survival times were the following: 1 h, 4 h, 1 day, 2 days and 1 week, 
formaldehyde fixation survival times were: 1 h, 1 day and 2 days. Sham-injured animals 
underwent the same operation procedures, but the filament was removed promptly after its 
insertion.  
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Tissue processing  
 Following transcardial perfusion, brains were removed from the skull after a 1-day 
delay. Two-thirds of the brains were fixed with glutaraldehyde, and then 150-µm vibratome 
sections were cut coronally from the caudal end. Every fifth vibratome section was stained by 
silver technique, which is specific and reproducible for “dark” neurons.  
 For electron microscopy, 2×2 mm
2
 areas of the caudate putamen and the temporal 
cortex were cut from several remaining vibratome sections, these areas being adjacent to 
those displaying silver-stained neurons. Ultrastructural investigations were carried out with a 
Jeol JEM 1200EX transmission electron microscope. 
 The caudal two-thirds of the brains were fixed with formaldehyde, and then were 
embedded in paraffin and cut at 10 µm. Every tenth section was stained with 0.1% cresyl 
violet, or with 1% acid fuchsin. For the demonstration of apoptosis, formaldehyde-fixed 
sections adjacent to those displaying damaged neurons according to the above staining 
methods were stained with an in situ cell death detection kit (TUNEL), with strict adherence 
to the instructions featured in the kit manual, and examined under a light microscope. 
 
3.2. RESULTS 
Light microscopic observations 
In the rats sacrificed immediately after removing of the surgical thread, the silver 
staining method homogeneously stained the soma-dendrite domain of a few stellate neurons 
in the right caudate putamen, and a few pyramidal neurons in the right temporal cortex.In the 
rats that survived for 1 h or longer, the damaged tissue areas (necrotic or excitotoxic) could be 
recognized on native, unstained tissue sections by their substantially increased phase contrast. 
In the rats with 1 day survival in those areas of the temporal cortex, contained numerous 
swollen dendritic and astrocytic processes and many normal-looking neurons, 
oligodendrocytes, pericytes and endothelial cells, in addition to several “dark” neurons. After 
1 h, 4 h and 1 day survival, the somata and dendrites of injured neurons were outlined by 
mitochondrion-sized silver grains, which are the characteristic features of the recovering 
“dark” neurons. In the necrotic areas after survival for 1 h, and in the excitotoxic areas of the 
temporal cortex after 1 and 4 h survival we observed many homogenously silver-stained 
neurons which individual somata or dendrites could hardly be distinguished. 
After 1 or 2 days of survival, the somata of a few stellate neurons and pyramidal 
neurons remained homogeneously silver-stained, while their dendrites were outlined by silver 
grains, most of which were much larger than mitochondria, a characteristic feature of dying 
“dark” neurons.After 1 day of survival, the peripheries (penumbra zones) of injured areas 
were overcrowded with silver-stained neuronal elements. In those animals, silver staining 
revealed the characteristic signs of both recovering and dying “dark” neurons, especially in 
the peripheral zones of excitotoxic areas. In the rats that survived for 6 days, only a few 
clusters of phagocytotic cells in a visibly normal environment were indicative of dead “dark” 
neurons.Toluidine blue homogeneously stained the nucleus, cytoplasm and main dendrites of 
the freshly produced “dark” neurons both in the temporal cortex and in the caudate putamen. 
In animals that survived for 2 days, the toluidine blue-stained neurons appeared to undergo 
fragmentation; while after 6 days of survival some fagocytotic cells were observable proving 
the presence of dying “dark” neurons. TUNEL-positive cell nuclei were present mainly in the 
penumbra zone of the necrotic foci, mostly in the rats that survived for 1 day. 
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Electronmicroscopic observations 
In the rats sacrificed immediately after the removal of the surgical thread, a few 
neurons displayed a dramatic compaction. In those neurons distances between ultrastructural 
elements were dramatically shrunken, the ER cisternae were contracted, while those of the 
Golgi cisternae were dilated, the mitochondria remained unchanged. The nuclei of such 
neurons contained several small chromatin clumps. After 1 h survival time, there were many 
dramatically compacted neurons. Unlike those in the immediately sacrificed rats, these 
displayed sequestered ribosomes and several slightly swollen mitochondria. Close to those 
tissue areas with increased phase contrast at 1 h and 4 h of reperfusion, the ER cisternae in 
several compacted neurons had virtually regained normal width. 
 In the rats that survived for 1 or 2 days, but not for 6 days, several normal-looking 
neuronal somata and dendrites contained mitochondrion-sized membranous whorls. A few of 
them appeared to be just leaving the soma or a dendrite of a neuron. In the same tissue areas a 
few “dark” neurons became even more compact, so that individual ultrastructural elements 
could not be distinguished within them, and exhibited many variously sized membrane-bound 
protrusions. Slightly swollen astrocytic processes that contained numerous glycogen particles 
surrounded these neurons. 
 In the 2-day rats, several of these protrusions had become separated into membrane-
bound, compact and homogeneous fragments. In the rats that survived for 6 days, such 
neurons and neuronal fragments were partly or completely engulfed by microglial cells, or by 
astrocytes. 
In the necrotic or excitotoxic tissue areas of the rats that survived for 1 day, a few 
“dark” neurons were even more compact and more electron dense, while others became 
swollen, and in part or fully disintegrated. Such neurons were surrounded by watery neuronal 
dendrites or extremely swollen astrocytic processes that did not contain glycogen particles. 
 In the rats that survived for 2 or 6 days, “dark” neurons underwent necrotic-like 
disintegration. In those rats that survived for 1 day, several neurons with a compacted 
ultrastructure in the penumbra zone of the necrotic area contained a few large, rounded 
(apoptotic) chromatin clumps. In the rats that survived for 2 days or longer, several neurons 
had undergone a necrotic-like disintegration. Others had fallen into membrane-bound, 
compact and homogenous fragments that were surrounded by glycogen-containing astrocytic 
processes. Those were partialy or completely engulfed by microglial cells or by astrocytes.  
 
3.3. DISCUSSION AND CONCLUSION 
By definition, ischemia means the complete arrest of blood circulation. However, in 
our experiment this was only partly true, because the blood flow was reduced in a different 
degree in the caudate putamen’s necrotic area, the temporal cortex citotoxic area, and in a 
visibly intact neighbouring areas. For this reason, the pathobiochemical cascade that initiates 
ultrastructural compaction might be quite different in these tissue areas. Although, the essence 
of the morphological events was the same in each freshly produced “dark” neuron both in 
stellate neurons in the caudate putamen and pyramidal neurons in the temporal cortex. 
Furthermore, they were in aggreement of the morphological pictures of “dark” neurons caused 
by other (mechanical, electric, hypoglicemic) noxae.  
From these observations we can conclude, that the formation of “dark” neurons has an 
initiation and an execution phase. The mechanism of initiation can be varied, while the 
mechanism of executive phase is independent on the phenotype, chemotype and function of 
the affected neurons. This fact strenghtens our former hypothesis pertaining to the formation 
of “dark” neurons.   
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One half of the “dark” neurons that are caused by traumatic brain injury, electric shock 
and hypoglicemia will regenerate. As the first event, the ER cisternae regain their original 
width. Thereafter, the degree of ultrastructural compaction gradually decreases. During this 
process, mitochondrion-sized membranous whorls appear in the somata and the main 
dendrites of the affected neurons and after 1 or 2 days they leave the neurons. In our case we 
observed the same morphological changes by recovering “dark” neurons. 
 The other half of the “dark” neurons caused by traumatic brain injury, electric shock 
and hypoglicemia will die. As impact of the above mentioned noxae, the dying portion of 
compacted neurons in non-necrotic, non-excitotoxic, respectively non-contusion brain areas 
will be removed in similar manner to apoptotic cells, which was found in our case too. We 
may draw the conclusion that “dark” neurons are not dying via the necrotic pathway, it was 
once thought that “dark” neurons in necrotic, cytotoxic, and contusioned brain areas are dying 
in a similar manner to necrotic neurons. In the case of the above mentioned physical noxae 
ultrastructural compaction is immediate, making the apoptotic cell death pathway 
unimaginable. Therefore, “dark” neurons must have their own dying mechanism. 
 In our case apoptotic cells in necrotic environment were removed in a similar manner 
to necrotic cells. Only residual chromatin lumps referred to their apoptotic origin. Namely, the 
necrotic environment forced a necrotic removing mechanism to neurons dying by apoptotic 
cell death pathway. By analogy, we assume that the necrotic environment pushes a necrotic 
removing mechanism to dying “dark” neurons. 
 
III. SUMMARY OF NOVEL FINDINGS 
 
1. In our experiments with a moderate CFP model, we found  that treatment with 100 µg 
PACAP i.c.v. 30 minutes post-injury significantly reduced the density of both APP and RMO-
14 IP axons. PACAP has a neuroprotective effect in both forms of TAI: in AS/B formation as 
well as in NFC. 
 The neuroprotective effect of PACAP was not significant in MLF. This can be 
explained by the fact that in this tract, the density of intact axons, their diameter and course is 
different than in the CSpT, where the neuroprotective effect proved to be significant. 
 Our results supported former observations from the impact acceleration model of TAI, 
that PACAP efficiently reduces the number of impaired axons in cases of both impaired 
intraaxonal transport and NFC caused by traumatic brain injury. 
 
2. In our experiments with Marmarou’s impact acceleration model we found that 
immediate or 30 minutes post-injury i.c.v. treatment with 100 µg/rat of L-2286 (a newly 
developed PARP inhibitor) significantly reduced the density of both APP and RMO-14 IP 
axons in both CSpT and MLF. Therefore, L-2286 has a neuroprotective effect in both forms 
of TAI: in AS/B formation as well as in NFC.  
 Treatment with 100 µg/rat L-2286 i.c.v. had a different reducing effect to the density 
of APP and RMO-14 IP axons. This fact suggests that these axonal damages are 
heterogeneous phenomenas, and in different neuronal fibers they will be „activated” with 
different chance.  
 The i.c.v. treatment with 100 µg/rat L-2286 also proved to be neuroptotective in 
behavioral tests. Namely, in the beam-balance test it significantly improved impaired motor 
functions, furthermore significantly reduced the raised anxiety level in the elevated plus-maze 
test.  
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3.  We made new observations about the formation and morphological aspects of “dark” 
neurons in transient focal cerebral ischemia model.  
The basic morphological features of every freshly produced “dark” neuron was the 
same in all examined areas (central, and peripheral areas of caudate putamen, in addition to 
cytotoxic areas of the temporal cortex, and its visibly intact neighbouring areas), despite the 
different blood flow rates. These features were in agreement with the morphological pictures 
of “dark” neurons caused by other injury-causing (mechanical, electric, hypoglicemic noxae) 
impacts.  
 From these observations, we conclude, that the formation of “dark” neurons has an 
initiation and an execution phase. The mechanism of inititation can be varied, while the 
mechanism of executing phase is independent from the type of initiating noxae, as well as the 
phenotype, chemotype and function of the affected neurons. This fact supports our former 
hypothesis pertaining to the formation of “dark” neurons. We assume that the necrotic 
environment pushes the dying “dark” neurons to a necrotic removing mechanism. 
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